Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
Key Highlights
- ➤Rosemont to acquire Aytu (AYTU) for $2.70 cash per share
- ➤$2.70 offer represents a 41.1% premium to Aytu’s 30-day VWAP
- ➤Aytu board unanimously approved the transaction
- ➤Closing anticipated in late December 2026, subject to tender conditions
- ➤Deal adds Aytu’s ADHD portfolio, MDD asset and US commercial platform
Expert Statements
Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals
“The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy. Aytu has built an established CNS adult and paediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities. Together with Rosemont’s product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete.”
Josh Disbrow, Chief Executive Officer of Aytu BioPharma
“This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
* Agreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share. * Proposed acquisition brings an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform. * Closing anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions in the tender offer. GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients’ needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.
The proposed acquisition represents a significant step in Rosemont’s global growth strategy, building on its established US presence and strengthening its position in the specialty pharmaceutical market. By bringing together complementary portfolios, expertise and commercial capabilities including omnichannel and digital marketing expertise, Rosemont aims to accelerate growth, expand its reach and create new opportunities across international markets.
Get started
Create a free account to read the full story.
